The relationship between expression and clinical parameters reveals that CD22 may contribute to lymph node metastasis, but is not related to depth of tumor invasion or clinical stage (p > 0.05, respectively). The gene discussed is CD22; the disease is metastatic malignant neoplasm in the lymph nodes.